|
Cushing’s Disease Research Highlights: ENDO 2023
This 30-minute CME program highlights the latest clinical research about Cushing’s disease.
Cushing’s disease is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary tumor that leads to excessive levels of cortisol.
This CME program, hosted by Lisa Machtigall, MD, Clinical Director, Neuroendocrine & Pituitary Tumor Clinical Center at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard Medical School, provides an overview of the latest cli... |
|
|
Call to Action for Health Equity: Racial Disparities in the Care of Patients with Cardiometabolic Disease
Cardiovascular disease is the leading cause of death for adults in the US. However, patients from minority populations with cardiovascular disease have disproportionately poor health outcomes and are particularly vulnerable to health disparities. Racial inequities in health also result in higher risk-burden in minority groups for metabolic syndromes such as Type 2 (adult-onset) diabetes, which increase the risk of cardiovascular disease. Health disparities in cardiometabolic care predominantly... |
|
|
Clinical Updates in Chronic Graft-versus-Host Disease and Applications for Academic and Community Practice
Target Audience
The target audience for this activity are hematologists, oncologists, immunologists, and bone-marrow transplant specialists.
Program Overview
Chronic graft-versus-host disease (cGvHD) is a common, multi-symptom complication of allogeneic transplantation that severely affects patient well-being. While the medical systems and resources differ between academic and community healthcare settings, clinicians practicing in both environments would benefit from education about rece... |
|
|
Cleveland Clinic 13th Annual Neurology Update
Cleveland Clinic’s 13th Annual Neurology Update features a faculty of more than a dozen thought leaders discussing the most current clinically focused information regarding diagnosis, medication and therapy for a wide variety of neurologic conditions. This comprehensive review will detail strategies, procedures and best practices throughout the specialty. Neurologists, general practitioners, nurses and physician assistants will all benefit from the latest information impacting the practice... |
|
|
Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma
ACTIVITY DESCRIPTION
Though treatment advances have improved outcomes for most patients, MM remains an incurable disease characterized by continuous relapse. However, the treatment landscape for relapsed/refractory MM (RRMM) has expanded in recent years, and patients who relapse and/or become refractory to initial therapies are benefiting from the increasing availability of a diverse range of novel agents, including B-cell maturation antigen (BCMA)"targeted immunotherapies. These agents ... |
|
|
Cleveland Clinic 27th Annual Diabetes Therapeutics, Technology and Surgery (Online Streaming On Demand)
For over a quarter century, Cleveland Clinic has been at the forefront of continuing education regarding the treatment and management of diabetes. Its world class faculty has designed the 27th Annual Diabetes Therapeutics, Technology and Surgery to provide up-to-date reviews of strategies and research relevant to this disease and its complications. The goal of this activity is to increase practitioners’ competence and clinical performance in the management of type 1 and type 2 diabetes. A... |
|